catalyst horizon
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research feb
estim feb
price data feb
rate updat feb
currenc amount express
methodolog valu compani
follow incyt fourth-quart result increas
fair valu estim per share reflect
time valu money updat estim cost
equiti revenu compani jakafi franchis
market jakavi outsid match
thank pipelin progress off-set higher
research develop cost believ incyt jak
inhibitor program includ jakafi next-gener
regimen strong efficaci first-in-class advantag
rare blood disord market uncertainti lead
pivot read-out incyt ido inhibitor drug combin
merck keytruda unfairli weigh compani
share view
total fourth-quart revenu grew year year
driven year-over-year growth jakafi sale
myelofibrosi patient continu major
contributor robust jakafi adopt continu uptak
polycythemia vera patient also tend stay
drug longer provid strong tailwind sequenti
basi jakafi sale roughli flat due announc
inventori stock third quarter despit news
celgen reviv competitor jak program fedratinib
remain confid jak franchis set
high bar new entrant model jakafi sale
toward bottom end manag billion
guidanc higher previou think limit
headwind result updat regul close
donut hole expect impact first-quart growth
although strong new patient demand remain key driver
jakafi sale potenti label expans acut graft-
versus-host-diseas year-end pend posit result
first half year provid anoth near-term
catalyst firm
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
focus discoveri develop small-molecul drug
firm lead drug jakafi treat two type rare blood cancer
partner novarti market drug includ rheumatoid
arthriti treatment olumi licens oncolog
drug iclusig chronic myeloid leukemia pipelin includ broad
array oncolog autoimmun program includ ido inhibitor
epacadostat next-gener jak inhibitor itacitinib
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
eye peel upcom pivot result incyt
ido program advanc melanoma expect
first half key driver valuat
trial compar ido/checkpoint inhibitor
combin checkpoint inhibitor monotherapi
believ trial need show compar efficaci
ctla drug regimen margin weaker efficaci coupl
superior safeti profil ctla combin could
also keep ido regimen competit posit
risk neg read-out ido combin
melanoma optimist expect
result believ investor cautiou use
melanoma conclus directli read
rest incyt ido inhibitor program either way
compani sever phase trial evalu
epacadostat combin checkpoint inhibitor
keytruda merck opdivo bristol imfinzi astrazeneca
across number oncolog indic
addit potenti jakafi label expans pivot
epacadostat result anticip two addit catalyst
year includ fda approv eli lilly-partn
rheumatoid arthriti drug baracitinib
incyt intern develop fgfr inhibitor cholangiocarcinoma
type ultra-rar cancer end year believ
bar competitor like upadacitinib
boast similar top-line efficaci increas research
develop forecast reflect grow late-
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
